Key insights from therapeutic drug monitoring in Crohn’s disease patients

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46–54 e42; quiz e30. PubMed PMID: 22001864.
   Google Scholar
• van Den Heuvel TRA, Jeuring SFG, Zeegers MP, et al. A 20-year temporal change analysis in incidence, presenting phenotype and mortality, in the Dutch IBDSL cohort-can diagnostic factors explain the increase in IBD incidence? J Crohns Colitis. 2017 Oct 1;11(10):1169–1179. PubMed PMID: 28430884.
   Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010 Feb;4(1):28–62. PubMed PMID: 21122489.
   Google Scholar
• van Bodegraven AA, van Everdingen JJ, Dijkstra G, et al. [Guideline ‘diagnosis and treatment of inflammatory bowel disease in adults’. I. Diagnosis and treatment]. Ned Tijdschr Geneeskd. 2010;154:A1899. PubMed PMID: 21029496.
   Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010 Apr 15;362(15):1383–1395. PubMed PMID: 20393175.
   Google Scholar
• van Schaik T, Maljaars JP, Roopram RK, et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis. 2014 Dec;20(12):2292–2298. PubMed PMID: 25230167.
   Google Scholar
• Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol. 2006 Jan 1;176(1):640–651. PubMed PMID: 16365460; PubMed Central PMCID: PMCPMC1965586.
   Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003 Apr;111(8):1133–1145. PubMed PMID: 12697733; PubMed Central PMCID: PMCPMC152932.
   Google Scholar
• Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004 Jun;26(3):311–318. PubMed PMID: 15167634.
   Google Scholar
• Dervieux T, Boulieu R. Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clin Chem. 1998 Dec;44(12):2511–2515. PubMed PMID: 9836719
   Google Scholar
• Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992 Nov 27;583(1):83–90. PubMed PMID: 1484095.
   Google Scholar
• Shipkova M, Armstrong VW, Wieland E, et al. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem. 2003 Feb;49(2):260–268. PubMed PMID: 12560349.
   Google Scholar
• Mao R, Guo J, Luber R, et al. 6-thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn’s disease. Inflamm Bowel Dis. 2018 Nov 29;24(12):2621–2627. PubMed PMID: 29788262.
   Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000 Apr;118(4):705–713. PubMed PMID: 10734022.
   Google Scholar
• Wong DR, Derijks LJ, Den Dulk MO, et al. The role of xanthine oxidase in thiopurine metabolism: a case report. Ther Drug Monit. 2007 Dec;29(6):845–848. PubMed PMID: 18043486.
   Google Scholar
• van Asseldonk DP, Sanderson J, de Boer NK, et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease–proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011 Apr;43(4):270–276. PubMed PMID: 20934926.
   Google Scholar
• Sanchez Rodriguez E, Rios Leon R, Mesonero Gismero F, et al. Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease. Gastroenterol Hepatol. 2018 Aug 11. DOI:10.1016/j.gastrohep.2018.06.013. PubMed PMID: 30107940.
   Google Scholar
• Yarur AJ, Gondal B, Hirsch A, et al. Higher thioguanine nucleotide metabolite levels are associated with better long-term outcomes in patients with inflammatory bowel diseases. J Clin Gastroenterol. 2018 Jul;52(6):537–544. PubMed PMID: 28723860.
   Google Scholar
• Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb;19(2):363–369. PubMed PMID: 22605661.
   Google Scholar
• Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007 Feb;5(2):209–214. PubMed PMID: 17296529.
   Google Scholar
• Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother. 1996 Sep;30(9):951–954. PubMed PMID: 8876853.
   Google Scholar
• Kreijne JE, Seinen ML, Wilhelm AJ, et al. Routinely established skewed thiopurine metabolism leads to a strikingly high rate of early therapeutic failure in patients with inflammatory bowel disease. Ther Drug Monit. 2015 Dec;37(6):797–804. PubMed PMID: 25853923.
   Google Scholar
• Herrlinger KR, Deibert P, Schwab M, et al. Remission maintenance by tioguanine in chronic active Crohn’s disease. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1459–1464. PubMed PMID: 12823147.
   Google Scholar
• van Asseldonk DP, Jharap B, Kuik DJ, et al. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Dig Liver Dis. 2011 Feb;43(2):110–115. PubMed PMID: 20739231.
   Google Scholar
• Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015 Oct;149(4):907–17 e7. PubMed PMID: 26072396.
   Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000 Jun 1;342(22):1627–1632. PubMed PMID: 10833208.
   Google Scholar
• McDonald JW, Tsoulis DJ, Macdonald JK, et al. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2012 Dec 12:CD003459. DOI:10.1002/14651858.CD003459.pub3. PubMed PMID: 23235598.
   Google Scholar
• Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014 Mar;146(3):681–688 e1. PubMed PMID: 24269926.
   Google Scholar
• Brooks AJ, Begg EJ, Zhang M, et al. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit. 2007 Oct;29(5):619–625. PubMed PMID: 17898653.
   Google Scholar
• Fischer M, Siva S, Cook GK, et al. Methotrexate polyglutamate monitoring in patients with Crohn’s disease. Clin Pharmacol Drug Dev. 2017 May;6(3):240–245. PubMed PMID: 27274011.
   Google Scholar
• Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40(10):723–751. PubMed PMID: 11707060.
   Google Scholar
• Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008 Nov;135(5):1493–1499. PubMed PMID: 18848553.
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541–1549. PubMed PMID: 12047962.
   Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004 Feb 26;350(9):876–885. PubMed PMID: 14985485.
   Google Scholar
• D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008 Feb 23;371(9613):660–667. PubMed PMID: 18295023.
   Google Scholar
• American Gastroenterological Association. Therapeutic drug monitoring in inflammatory bowel disease: clinical decision support tool. Gastroenterology. 2017 Sep;153(3):858–859. PubMed PMID: 28778399.
   Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003 Feb 13;348(7):601–608. PubMed PMID: 12584368.
   Google Scholar
• Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn’s disease. Inflamm Bowel Dis. 2013 May;19(6):1112–1122. PubMed PMID: 23584130.
   Google Scholar
• Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther. 2014 Sep;40(6):620–628. PubMed PMID: 25039584.
   Google Scholar
• Papamichael K, Cheifetz AS. Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy. Am J Gastroenterol. 2017 May;112(5):673–676. PubMed PMID: 28220781.
   Google Scholar
• Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013 Jun;108(6):962–971. PubMed PMID: 23419382.
   Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017 Sep;153(3):827–834. PubMed PMID: 28780013.
   Google Scholar
• Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017 Sep;153(3):835–857 e6. PubMed PMID: 28774547.
   Google Scholar
• D’Haens G, Vermeire S, Lambrecht G, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018 Apr;154(5):1343–1351 e1. PubMed PMID: 29317275.
   Google Scholar
• Roblin X, Boschetti G, Duru G, et al. Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study. Inflamm Bowel Dis. 2017 Nov;23(11):2048–2053. PubMed PMID: 28945636.
   Google Scholar
• Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016 Apr;14(4):550–557 e2. PubMed PMID: 26538204.
   Google Scholar
• Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2015 Mar;27(3):242–248. PubMed PMID: 25569569.
   Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015 Jun;148(7):1320–9 e3. PubMed PMID: 25724455.
   Google Scholar
• Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017 Apr;45(7):933–940. PubMed PMID: 28211593.
   Google Scholar
• Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014 Jul;20(7):1288–1295. PubMed PMID: 24831559.
   Google Scholar
• Bodini G, Giannini EG, Savarino V, et al. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. Scand J Gastroenterol. 2016 Sep;51(9):1081–1086. PubMed PMID: 27207330.
   Google Scholar
• Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014 Mar;12(3):423–31 e1. PubMed PMID: 24184736.
   Google Scholar
• Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010 Feb 1;24(1):23–39. PubMed PMID: 20055530.
   Google Scholar
• Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002 Jun;1(6):457–462. PubMed PMID: 12119747.
   Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007 Jul 19;357(3):239–250. PubMed PMID: 17634459.
   Google Scholar
• Kariyawasam VC, Ward MG, Blaker PA, et al. Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing Crohn’s disease. Inflamm Bowel Dis. 2017 Sep;23(9):1555–1565. PubMed PMID: 28786865.
   Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014 Feb;146(2):392–400 e3. PubMed PMID: 24512909.
   Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007 Sep;56(9):1232–1239. PubMed PMID: 17299059; PubMed Central PMCID: PMCPMC2701613.
   Google Scholar
• Roblin X, Boschetti G, Williet N, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017 Jul;46(2):142–149. PubMed PMID: 28449228.
   Google Scholar
• Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1118–24 e3. PubMed PMID: 25562796.
   Google Scholar
• Watanabe K, Matsumoto T, Hisamatsu T, et al. Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2018 Apr;16(4):542–549 e1. PubMed PMID: 29104132.
   Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013 Aug 22;369(8):711–721. PubMed PMID: 23964933.
   Google Scholar
• Dreesen E, Gils A. Blocking alpha4beta7 integrin through vedolizumab: necessary but not sufficient? J Crohns Colitis. 2017 Aug 1;11(8):903–904. PubMed PMID: 28333273.
   Google Scholar
• Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1750–1757 e3. PubMed PMID: 27890854.
   Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016 Nov 17;375(20):1946–1960. PubMed PMID: 27959607.
   Google Scholar
• de Boer NKH, Peyrin-Biroulet L, Jharap B, et al. Thiopurines in inflammatory bowel disease: new findings and perspectives. J Crohns Colitis. 2018 Apr 27;12(5):610–620. PubMed PMID: 29293971.
   Google Scholar
• Holmstrom RB, Mogensen DV, Brynskov J, et al. Interactions between thiopurine metabolites, adalimumab, and antibodies against adalimumab in previously infliximab-treated patients with inflammatory bowel disease. Dig Dis Sci. 2018 Jun;63(6):1583–1591. PubMed PMID: 29564674.
   Google Scholar
• van Asseldonk DP, Seinen ML, de Boer NK, et al. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. J Crohns Colitis. 2012 Feb;6(1):95–101. PubMed PMID: 22261533.
   Google Scholar
• Ward MG, Warner B, Unsworth N, et al. Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017 Jul;46(2):150–161. PubMed PMID: 28481014.
   Google Scholar